Paysign's strategic focus on Plasma and Patient Affordability programs has driven significant growth. Read more to see why PAYS stock is a Buy.

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare. ...

But ironically, the company has benefited from winning tenders to counter the impact of the avian flu pandemic which has ...

CSL consistency isn’t winning over investors, Ryan Stokes explains the new dump truck dance, and Macquarie’s return on equity ...

By focusing on dominant ASX shares like CSL, Goodman Group, WiseTech Global, and Xero, investors can build a portfolio of high-quality stocks that have the potential to compound wealth over the ...

Due to the planned CSL transition, Plasma revenue declined 9% in the quarter ... and that's just a function of pay-for-performance and the fact that we're not where we need to be across the ...

Greg Leyh likes to screw around with voltage and electric fields and plasma. In his time he's built some of the world's biggest Tesla coils, huge towering transformers that throw off terrifying webs ...

We believe CSL's valuation multiple de-rate is onerous considering the growth outlook, particularly for IG therapies. Key risks include: (1) US inflation impacting plasma donor fees, (2 ...

Learn More CSL Ltd (ASX: CSL) shares couldn't avoid the broader market sell-off on Monday. Shares in the S&P/ASX 200 Index (ASX: XJO) biotech stock ended the day down 1.4%, trading for $276.42 apiece.

#1. CSL Key milestones: 2007: CSL hit $100 before its 3-for-1 split. 2015: CSL hit $100 (again) 2018: Cracked $200. 2020: First surpassed $300. Note: CSL would technically be above $500 were it not ...

The Experimental Advanced Superconducting Tokamak (EAST), often referred to as China’s 'artificial sun,' successfully sustained plasma for a record 1,000 seconds, or over 17 minutes. This ...